Vaccine Stocks Rebound as Merkel Opposes Waiver of Patents
(Bloomberg) -- Shares of Covid-19 vaccine developers got some relief after the German chancellor opposed a U.S. proposal to waive patent protections for coronavirus shots.
Chinese vaccine makers rebounded after slumping Thursday on the news that the U.S. would support lifting the intellectual property protections. The Biden administration's plan would create “severe complications” for the production of vaccines, a German government spokeswoman said Thursday in an email.
Shanghai Fosun Pharmaceutical Group Co., which has the rights to develop and market BioNTech SE's shot in China, advanced as much as 7% in Hong Kong after sinking 14% the previous day. Walvax Biotechnology Co. gained 0.5% in Shanghai after an 11% slump Thursday.
Vaccine makers' stocks in Europe and the U.S. bounced a bit in late trading Thursday after the German government announced Chancellor Angela Merkel's opposition. On Friday, AstraZeneca Plc rose again in London, gaining 0.4%, while French developer Valneva SE jumped 5.1%. Among U.S.-listed companies, CureVac NV advanced 5.9% in German trading from its closing price in New York, Novavax Inc. rose 2.6%, BioNTech climbed 1.7% and Pfizer Inc. was little changed.
Before Merkel's announcement, some analysts had pointed out that lifting patent protections wasn't a done deal. The Biden administration's plans will only open up a negotiation at the WTO and other countries and members remain unwilling, said Barclays Plc analyst Carter Gould in a note.
With many countries struggling with a resurgence of the virus, U.S. Trade Representative Katherine Tai said Wednesday the Biden administration supported the effort at the World Trade Organization to waive the patent rights. The European Union said Thursday it was willing to participate.
Big Business
Vaccines have been a big business for the firms that make them, with Pfizer, BioNTech's partner outside of China, raising its forecast for 2021 vaccine sales to $26 billion just this week. AstraZeneca has pledged not to profit from its Covid shot during the pandemic.
Read more: Analysts say investor fears of U.S. vaccine waiver support are overblown
The International Federation of Pharmaceutical Manufacturers & Associations condemned the move lift IP protections as “disappointing.”
“A waiver is the simple but the wrong answer to what is a complex problem,” the group said in a statement. “Waiving patents of Covid-19 vaccines will not increase production nor provide practical solutions needed to battle this global health crisis.”
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.